OBJECTIVE: In order to observe the relationship between MTHFR promoter and DN, the determinations on MTHFR promoter methylation level and expression of HCY from DN patients have been carried out. METHODS: According to the Diabetes diagnosis and classification standard from WHO in 1999, 85 patients with DM diagnosed by Endocrinology and 30 healthy participants from our medical examination center were chosen as control specimen to study in this paper. All this specimen were divided into A, B, C and D four groups , which are corresponding simple diabetes mellitus group (SDM), early diabetic nephropathy group (EDN), clinical diabetic nephropathy group (CDN) and normal control group. And then, all common materials and clinical experiments data have been collected respectively. (1) Extracted the peripheral blood DNA of each group and determinate the methylation status of MTHFR gene promoter by PCR (MSP). (2) Determinated the serum HCY protein expression of each group. RESULTS: (1) The MTHFR promoter methylation of SDM and diabetic nephropathy group are wear off comparied with normal control group. And MTHFR promoter was in demethylation state in normal control group, a slightly weak in SDN, a obviously weak in early diabetic nephropathy group; the MTHFR promoter was in methylation state in clinical diabetic nephropathy group. (2) The HCY protein of simple diabetes mellitus group, early diabetic nephropathy group and clinical diabetic nephropathy group are Pitch with normal control group. HCY protein level of each group are as 7.41±1.61 umol/L, 10.34±2.89 umol/L, 10.95±5.89 umol/L and 13.03±6.14 umol/L corresponding normal control group, simple diabetes mellitus group, early diabetic nephropathy group and clinical diabetic nephropathy group. And there is no statistical significance about the differences among four groups. CONCLUSION: The demethylation state of MTHFR promoter was obviously weaker in clinical diabetic nephropathy group than in SDM. The level of serum HCY was obviously higher in clinical diabetic nephropathy group than in SDM. It suggested that MTHFR promoter demethylation may be involoed in the pathogenesis of DN.
OBJECTIVE: In order to observe the relationship between MTHFR promoter and DN, the determinations on MTHFR promoter methylation level and expression of HCY from DN patients have been carried out. METHODS: According to the Diabetes diagnosis and classification standard from WHO in 1999, 85 patients with DM diagnosed by Endocrinology and 30 healthy participants from our medical examination center were chosen as control specimen to study in this paper. All this specimen were divided into A, B, C and D four groups , which are corresponding simple diabetes mellitus group (SDM), early diabetic nephropathy group (EDN), clinical diabetic nephropathy group (CDN) and normal control group. And then, all common materials and clinical experiments data have been collected respectively. (1) Extracted the peripheral blood DNA of each group and determinate the methylation status of MTHFR gene promoter by PCR (MSP). (2) Determinated the serum HCY protein expression of each group. RESULTS: (1) The MTHFR promoter methylation of SDM and diabetic nephropathy group are wear off comparied with normal control group. And MTHFR promoter was in demethylation state in normal control group, a slightly weak in SDN, a obviously weak in early diabetic nephropathy group; the MTHFR promoter was in methylation state in clinical diabetic nephropathy group. (2) The HCY protein of simple diabetes mellitus group, early diabetic nephropathy group and clinical diabetic nephropathy group are Pitch with normal control group. HCY protein level of each group are as 7.41±1.61 umol/L, 10.34±2.89 umol/L, 10.95±5.89 umol/L and 13.03±6.14 umol/L corresponding normal control group, simple diabetes mellitus group, early diabetic nephropathy group and clinical diabetic nephropathy group. And there is no statistical significance about the differences among four groups. CONCLUSION: The demethylation state of MTHFR promoter was obviously weaker in clinical diabetic nephropathy group than in SDM. The level of serum HCY was obviously higher in clinical diabetic nephropathy group than in SDM. It suggested that MTHFR promoter demethylation may be involoed in the pathogenesis of DN.
Entities:
Keywords:
DNA methylation; Diabetes meilltus; diabetic nephropathy; homocysteine; methylenetetrahydrofolate reductase
Authors: Srimoyee Ghosh; Allan J Yates; Michael C Frühwald; Jeffrey C Miecznikowski; Christoph Plass; Dominic Smiraglia Journal: Epigenetics Date: 2010-08-16 Impact factor: 4.528
Authors: Sandra Hirsch; Ana María Ronco; Carlos Guerrero-Bosagna; María Pía de la Maza; Laura Leiva; Gladys Barrera; Miguel Llanos; M Angelica Alliende; Francisca Silva; Daniel Bunout Journal: Nutrition Date: 2008-07-23 Impact factor: 4.008
Authors: Tainá Gomes Diniz; Alexandre Sérgio Silva; Mayara Karla Dos Santos Nunes; Mateus Duarte Ribeiro; João Modesto Filho; Rayner Anderson Ferreira do Nascimento; Cecília Neta Alves Pegado Gomes; Isabella Wanderley de Queiroga Evangelista; Naila Francis Paulo de Oliveira; Darlene Camati Persuhn Journal: Front Physiol Date: 2021-01-12 Impact factor: 4.566
Authors: Mayara Karla Dos Santos Nunes; Alexandre Sérgio Silva; Isabella Wanderley de Queiroga Evangelista; João Modesto Filho; Cecília Neta Alves Pegado Gomes; Rayner Anderson Ferreira do Nascimento; Rafaella Cristhine Pordeus Luna; Maria José de Carvalho Costa; Naila Francis Paulo de Oliveira; Darlene Camati Persuhn Journal: Diabetol Metab Syndr Date: 2017-10-18 Impact factor: 3.320
Authors: Herlanny Santana Bezerra; Caroline Severo de Assis; Mayara Karla Dos Santos Nunes; Isabella Wanderley de Queiroga Evangelista; João Modesto Filho; Cecília Neta Alves Pegado Gomes; Rayner Anderson Ferreira do Nascimento; Rafaella Cristhine Pordeus Luna; Maria José de Carvalho Costa; Naila Francis Paulo de Oliveira; Darlene Camati Persuhn Journal: Diabetol Metab Syndr Date: 2019-01-15 Impact factor: 3.320